DUBLIN – You could call it the Meatloaf interpretation of clinical trial data. Neovacs SA missed one of two co-primary endpoints on a phase IIb trial of interferon-alpha kinoid (IFNalpha kinoid) in systemic lupus erythematosus (SLE) but stressed that the study achieved "three out of four clinical objectives." The data are, it stated, sufficiently robust to justify moving the program into a phase III trial.